Loading…
BioLineRx Ltd. is projected to rise to $3.17 by 2027, a +3% move from its current price of $3.09. BLRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.99 | $3.09 | $3.19 | -0.01% |
| Jul 14 | $2.95 | $3.09 | $3.23 | -0.02% |
| Jul 15 | $2.92 | $3.09 | $3.27 | -0.03% |
| Jul 16 | $2.90 | $3.09 | $3.29 | -0.04% |
| Jul 17 | $2.87 | $3.09 | $3.32 | -0.05% |
| Jul 18 | $2.85 | $3.09 | $3.34 | -0.07% |
| Jul 19 | $2.83 | $3.09 | $3.36 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.83 | $3.09 | $3.36 | -0.08% |
| Week 2 | $2.73 | $3.09 | $3.48 | -0.15% |
| Week 3 | $2.66 | $3.08 | $3.57 | -0.23% |
| Week 4 | $2.60 | $3.08 | $3.65 | -0.31% |
| Week 5 | $2.54 | $3.08 | $3.73 | -0.38% |
| Week 6 | $2.49 | $3.08 | $3.79 | -0.46% |
| Week 7 | $2.45 | $3.07 | $3.85 | -0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioLineRx Ltd. is a healthcare company focused on developing and commercializing therapeutics for oncology and rare diseases. Its pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers, and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for sickle cell disease, Phase 2b clinical trial for pancreatic cancer, as well as completed Phase 3 clinical trial for multiple myeloma.
The company also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd. (BLRX) operates in the Healthcare sector as a biopharmaceutical company focused on oncology and rare diseases. The stock’s current price is $3.12 per share, with a market cap of $14.02M and a rank of 5022.
The price action shows a 30-day range from $2.41 to $4.03, indicating meaningful volatility around the current level. The near-term technical picture features a neutral stance, with RSI(14) at 50 and price action near key moving averages: SMA50 at $3.00 and SMA200 at $3.12. Support sits at $2.63 and resistance at $3.78, framing the immediate risk/reward.
Overall price outlook derives from a year-by-year forecast that tracks a path from a 2026 average of $3.12 toward higher levels in later years, with bullish sentiment expanding from 2030 onward and a substantial long-horizon upside implied by the 2050 forecast of $14.86 on average, and a max forecast of $31.86 during that period.
A major floor 29.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 22.3% above — a clean break opens room to run.
A major ceiling 31.5% above — clearing it would confirm fresh momentum.
Key BLRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BLRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.09 | Sell | $3.09 | Sell |
| MA 10 | $3.13 | Sell | $3.12 | Sell |
| MA 20 | $3.18 | Sell | $3.15 | Sell |
| MA 50 | $3.15 | Sell | $3.08 | Buy |
| MA 100 | $2.84 | Buy | $3.02 | Buy |
| MA 200 | $3.08 | Buy | $3.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.60 | Neutral |
| Stoch RSI (14) | 27.41 | Neutral |
| CCI (20) | -61.16 | Neutral |
| Williams %R (14) | -77.78 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -5.21 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 22.22 | Neutral |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 45.71 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 3.03 | Buy |
| ADX (14) | 8.40 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is Neutral, with RSI(14) at 50 and the price interacting with the near-term moving averages. The SMA50 sits at $3.00 while the SMA200 is $3.12, signaling a balanced stance rather than a clear breakout.
In the immediate range, the 30-day window spans from a low of $2.41 to a high of $4.03, outlining a modestly wide trading band. Support is identified at $2.63 and resistance at $3.78, providing defined levels for risk management in the short term. The stock’s annualized volatility is 70%, underscoring notable price fluctuations within the month-long horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.18 | $3.09 | $3.92 | 0% | Neutral | |
| $2.48 | $3.17 | $4.31 | +3% | Neutral | |
| $2.64 | $3.50 | $4.96 | +13% | Neutral | |
| $2.43 | $3.30 | $4.85 | +7% | Neutral | |
| $2.86 | $3.98 | $6.01 | +29% | Bullish | |
| $3.47 | $4.94 | $7.64 | +60% | Bullish | |
| $3.51 | $5.11 | $8.06 | +65% | Bullish | |
| $3.52 | $5.23 | $8.42 | +69% | Bullish | |
| $3.31 | $5.01 | $8.21 | +62% | Bullish | |
| $3.41 | $5.25 | $8.76 | +70% | Bullish | |
| $4.64 | $7.78 | $13.90 | +152% | Bullish | |
| $7.98 | $15.54 | $30.69 | +403% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.18 | $3.09 | $3.80 | +0.00% |
| August 2026 | $2.68 | $3.18 | $3.88 | +2.80% |
| September 2026 | $2.56 | $3.06 | $3.79 | -3.69% |
| October 2026 | $2.54 | $3.06 | $3.83 | +0.06% |
| November 2026 | $2.59 | $3.13 | $3.96 | +2.36% |
| December 2026 | $2.52 | $3.07 | $3.92 | -1.87% |
Click any year to see its month-by-month BLRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BLRX is projected to trade between $2.18 and $3.92, averaging $3.09 — a potential gain of 0% from today's $3.09. A consolidation phase looks the most probable path here.
BioLineRx Ltd.'s 2027 outlook centres on $3.17, within a $2.48 to $4.31 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2028, BLRX could reach as high as $4.96, with a base case around $3.50 and support toward $2.64 — roughly +13% from $3.09. A consolidation phase looks the most probable path here.
Expect BLRX to range from $2.43 to $4.85 through 2029. The $3.30 average target implies a +7% move from current prices. That is -5% versus the projected 2028 average. Price action looks broadly range-bound.
The BLRX price prediction for 2030 points to an average of $3.98 (low $2.86, high $6.01) — a potential gain of +29% on today's $3.09. Buyers look set to stay in control over this stretch.
In 2031, BLRX is projected to trade between $3.47 and $7.64, averaging $4.94 — a potential gain of +60% from today's $3.09. That is up +24% on the projected 2030 average. Momentum favours further upside here.
BioLineRx Ltd.'s 2032 outlook centres on $5.11, within a $3.51 to $8.06 range. That is up +3% on the projected 2031 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BLRX could reach as high as $8.42, with a base case around $5.23 and support toward $3.52 — roughly +69% from $3.09. Momentum favours further upside here.
Expect BLRX to range from $3.31 to $8.21 through 2034. The $5.01 average target implies a +62% move from current prices. That is -4% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BLRX price prediction for 2035 points to an average of $5.25 (low $3.41, high $8.76) — a potential gain of +70% on today's $3.09. Momentum favours further upside here.
In 2040, BLRX is projected to trade between $4.64 and $13.90, averaging $7.78 — a potential gain of +152% from today's $3.09. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioLineRx Ltd.'s 2050 outlook centres on $15.54, within a $7.98 to $30.69 range. That is up +100% on the projected 2040 average. That marks a +403% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BLRX today (≈ 323.624595 BLRX) could be worth
$5,029.98
+$4,029.98 (+403%) by 2050 · US Dollar
Based on the average projected BLRX price of $15.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BLRXwould be worth at today's price.
$1,000 invested in BLRX on Jul 10, 2025 (≈ 204.918028 BLRX) would be worth
$633.2
-$366.8 (-36.7%) today · 0.63× · US Dollar
Based on a BLRX entry price of $4.88 vs. today's $3.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.29 | $939.21 | -6.1% |
| 1 month ago | $3.28 | $942.07 | -5.8% |
| 3 months ago | $2.29 | $1,349.35 | +34.9% |
| 6 months ago | $2.86 | $1,080.42 | +8.0% |
| 1 year ago | $4.88 | $633.2 | -36.7% |
| All time (5.0y) ago | $117.2 | $26.37 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BLRX forecast.
Our base-case forecast reaches $6.20 around 2040.
Implied market cap at $6.20: $26.98M
The multi-year forecast paints a gradually improving trajectory with mixed returns through the mid-term before a clearly bullish phase emerges. In 2026 the average target is $3.12 with a 0% ROI and Neutral sentiment, followed by gradual gains into 2028 (avg $3.46, ROI 11.2) and a dip in 2029 (avg $3.05, ROI -2.2).
From 2030 onward, the outlook strengthens, with 2030 at $3.97 (ROI 27.6, Bullish) and continued upside into 2031 ($5.03, ROI 61.4) and 2032 ($4.95, ROI 58.8). The uptrend persists through 2033 ($5.18, ROI 66.4) and 2034 ($4.80, ROI 54.1), before 2035 ($4.89, ROI 57) maintains a bullish tone.
The long-range projection becomes more pronounced in 2040 with an average of $7.39 (ROI 137.3) and culminates in 2050 at an average of $14.86 (ROI 377.1), with a max of $31.86. These figures imply a strong upside in the long term under a bullish scenario, but as with all forecasts they are estimates, not guarantees, and carry uncertainty and risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.97 with a min of $2.72 and a max of $6.29, and a 27.6% ROI with a Bullish sentiment.
The forecast presents a mixed near term with 2026–2029 averages around $3.12, $3.19, $3.46, and $3.05 and ROIs of 0%, 2.3%, 11.2%, and -2.2%. From 2030 onward the outlook is Bullish, with notable upside by 2040 and 2050, but these are estimates and not guaranteed.
Yes, the long-range forecast includes a 2050 max of $31.86, so a $10 target is within the projected range given the max values, though it is not guaranteed.
The 2026 forecast lists an average of $3.12, with a min of $2.18 and a max of $3.93, and a 0% ROI with Neutral sentiment.
The 30-day outlook is Neutral, with RSI(14) at 50, SMA50 at $3.00, SMA200 at $3.12, and a 30-day range from $2.41 to $4.03. Support is $2.63 and resistance is $3.78, with annualized volatility at 70%.
BioLineRx Ltd. Community Discussion
0Share your BioLineRx Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.